Friday, 16 October 2026European Markets

XXL Stock Bearish Momentum With A 10% Slide So Far On Thursday

Loading stream...

(VIANEWS) - Shares of XXL (Oslo Børs Benchmark Index_GI: XXL.OL) dropped by a staggering 10.35% to kr2.58 at 13:40 EST on Thursday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is sliding 0.51% to kr1,172.17, after three successive sessions in a row of gains. This seems, up until now, a somewhat negative trend exchanging session today.

XXL's last close was kr2.88, 76% under its 52-week high of kr12.00.

About XXL

XXL ASA operates as a sports retailer. It offers sports equipment and sportswear for various sports, including running, football, golf, water sports, racket sports, and ice hockey; and fitness equipment, including treadmills and rowing machines, as well as food supplements and nutrition. The company also provides clothes for men, women, and children for baselayers, outerwear, casual wear, sportswear, and swimwear, as well as lifestyle shoes and winter shoes; outdoor and hunting products for fishing, wilderness living, and camping, such as tents, lavvos, sleeping bags, backpacks, cooking equipment as well as climbing gear; and hunting products, including firearms and ammunition, clothes, binoculars, optics, knives, and axes. In addition, it offers skis and ski accessories, such as shoes, poles, clothes, and other equipment for cross-country and downhill skiing, as well as snowboarding; high-end and everyday bikes comprising hybrid bikes, mountain bikes, city bikes, and electric bikes for children, women, and men; and bike equipment, such as helmets, shoes, spare parts, and clothes. Further, the company provides products that connect technology and sports/outdoor activities, including sport watches, action cameras, drones, GPS, earplugs and headphones, portable loudspeakers, sunglasses, pulse meters, power banks, and cycle computers. As of December 31, 2021, it operated 92 stores, including 37 stores in Norway, 30 stores in Sweden, 17 stores in Finland, and 8 stores in Austria, as well as e-commerce websites, such as xxl.no, xxl.se, xxl.fi, xxl.dk, and xxlsports.at. The company was founded in 2000 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, XXL has a trailing twelve months EPS of kr1.134.

PE Ratio

XXL has a trailing twelve months price to earnings ratio of 2.28. Meaning, the purchaser of the share is investing kr2.28 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -2.04%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter is 18.6% and a drop 191.7% for the next.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Jun 3, 2022, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 15%.

Volume

Today's last reported volume for XXL is 1554678 which is 160.51% above its average volume of 596774.

More news about XXL (XXL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com